Novavax, Inc.
Novavax is a biotechnology company focused on the development of vaccines and treatments for infectious diseases.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Novavax's stock with a target price of $13.43, indicating potential growth.
Financial Health
Novavax is achieving strong revenue and cash flow, indicating solid financial performance and stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NVAX
Pediatric Vaccine Rollout
This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Published: July 11, 2025
Explore BasketBuffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: July 1, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline and R&D
Novavax's future depends on clinical progress and approvals; successful trials can drive value, though outcomes are uncertain and can affect share price sharply.
Contract‑Led Revenue
Government and partner deals have been a major revenue source, offering near‑term visibility but also creating lumpiness and dependence on external funding.
Manufacturing & Scale
Scaling production is central to commercial success; manufacturing or supply hiccups can delay launches and revenue, so operational risk is material.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
